Q1 2025 Evotec SE Earnings Call Transcript
Key Points
- Evotec SE (EVO) has made significant progress in its protein degradation collaboration with BMS, showcasing its strategy of technology leadership.
- The company received a grant from the Korean government to develop novel antibody treatments for lung fibrosis, highlighting its capabilities in drug discovery.
- Just Evotec Biologics delivered strong growth in Q1 2025, with revenues slightly ahead of expectations.
- Evotec SE (EVO) is leveraging cutting-edge technology and AI-driven innovation to accelerate drug discovery and improve success probabilities.
- The company has implemented significant cost-saving measures, including site closures and headcount reductions, which are expected to positively impact future financials.
- Evotec SE (EVO) experienced a 4% decrease in group revenues in Q1 2025 compared to Q1 2024, primarily due to a decline in shared R&D revenue.
- The market for shared R&D remains soft, resulting in revenue decline and performance slightly below expectations.
- The company faces temporary lower BMS revenue, which is expected to continue in the midterm.
- Evotec SE (EVO) has a temporarily elevated net debt leverage, with a net debt of EUR107 million.
- The company is operating in a cautious market environment with conservative spending from clients, impacting revenue growth.
Ladies and gentlemen, welcome to the Evote SE quarterly statement Q1 2025 conference call. I am George, the Chorus Call operator.
I would like to remind you that all participants will be listening to the mode and the conference is being recorded. The presentation will be followed by Q&A session. (Operator Instructions)
The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Volker Braun, Head of IR & ESG. Please go ahead.
Thank you, George, and good day, good afternoon to all of you following our Q1 2025 results webcast today. Only three weeks after the presentation of our strategic review in April, we will be picking up on the discussions we had in the meantime with some of you. And with that, I think I can move on to slide 2 in the presentation. As usual, it's my duty to point to the disclaimer and the cautionary note regarding forward-looking statements, which you find on that slide.
And with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
